JP2018519254A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519254A5 JP2018519254A5 JP2017557067A JP2017557067A JP2018519254A5 JP 2018519254 A5 JP2018519254 A5 JP 2018519254A5 JP 2017557067 A JP2017557067 A JP 2017557067A JP 2017557067 A JP2017557067 A JP 2017557067A JP 2018519254 A5 JP2018519254 A5 JP 2018519254A5
- Authority
- JP
- Japan
- Prior art keywords
- xaa
- cys
- absent
- peptide
- tyr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 74
- 150000003839 salts Chemical class 0.000 description 54
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 42
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 24
- WNNNWFKQCKFSDK-UHFFFAOYSA-N allylglycine Chemical compound OC(=O)C(N)CC=C WNNNWFKQCKFSDK-UHFFFAOYSA-N 0.000 description 22
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 18
- -1 C12 alkyl carboxylic acid Chemical class 0.000 description 16
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 16
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 16
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 12
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 11
- 229960001639 penicillamine Drugs 0.000 description 11
- 210000001072 colon Anatomy 0.000 description 9
- 206010036772 Proctalgia Diseases 0.000 description 8
- 206010013554 Diverticulum Diseases 0.000 description 7
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 6
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 6
- 108010077895 Sarcosine Proteins 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 6
- 229960002591 hydroxyproline Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229940043230 sarcosine Drugs 0.000 description 6
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 206010021518 Impaired gastric emptying Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- YIYBQIKDCADOSF-UHFFFAOYSA-N alpha-Butylen-alpha-carbonsaeure Natural products CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 description 4
- 208000001288 gastroparesis Diseases 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- YIYBQIKDCADOSF-ONEGZZNKSA-N trans-pent-2-enoic acid Chemical compound CC\C=C\C(O)=O YIYBQIKDCADOSF-ONEGZZNKSA-N 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 208000005615 Interstitial Cystitis Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- HVAMZGADVCBITI-UHFFFAOYSA-N pent-4-enoic acid Chemical compound OC(=O)CCC=C HVAMZGADVCBITI-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 208000037911 visceral disease Diseases 0.000 description 3
- 206010058019 Cancer Pain Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 2
- 206010051922 Hereditary non-polyposis colorectal cancer syndrome Diseases 0.000 description 2
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- 201000005027 Lynch syndrome Diseases 0.000 description 2
- 208000030053 Opioid-Induced Constipation Diseases 0.000 description 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 2
- 208000000450 Pelvic Pain Diseases 0.000 description 2
- 206010034310 Penile pain Diseases 0.000 description 2
- 208000037062 Polyps Diseases 0.000 description 2
- 206010054048 Postoperative ileus Diseases 0.000 description 2
- 206010036968 Prostatic pain Diseases 0.000 description 2
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 2
- 206010043345 Testicular pain Diseases 0.000 description 2
- 206010046477 Urethral syndrome Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 208000020629 overactive bladder Diseases 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000019751 Anorectal disease Diseases 0.000 description 1
- 206010005063 Bladder pain Diseases 0.000 description 1
- 206010011796 Cystitis interstitial Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 206010036783 Proctitis ulcerative Diseases 0.000 description 1
- 208000015815 Rectal disease Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 208000026555 breast adenosis Diseases 0.000 description 1
- 208000013507 chronic prostatitis Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 208000023506 generalized abdominal pain Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 108010091748 peptide A Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 208000022170 stress incontinence Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 229940126158 β3 adrenergic receptor agonist Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156077P | 2015-05-01 | 2015-05-01 | |
| US62/156,077 | 2015-05-01 | ||
| PCT/US2016/030061 WO2016178979A1 (en) | 2015-05-01 | 2016-04-29 | Compositions for colon cleansing and the treatment of gastrointestinal disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020165328A Division JP2020203954A (ja) | 2015-05-01 | 2020-09-30 | 結腸洗浄及び胃腸障害の治療のための組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519254A JP2018519254A (ja) | 2018-07-19 |
| JP2018519254A5 true JP2018519254A5 (enExample) | 2019-05-30 |
| JP6930919B2 JP6930919B2 (ja) | 2021-09-01 |
Family
ID=55953439
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557067A Active JP6930919B2 (ja) | 2015-05-01 | 2016-04-29 | 結腸洗浄及び胃腸障害の治療のための組成物 |
| JP2020165328A Withdrawn JP2020203954A (ja) | 2015-05-01 | 2020-09-30 | 結腸洗浄及び胃腸障害の治療のための組成物 |
| JP2022107644A Pending JP2022121734A (ja) | 2015-05-01 | 2022-07-04 | 結腸洗浄及び胃腸障害の治療のための組成物 |
| JP2023208395A Active JP7862355B2 (ja) | 2015-05-01 | 2023-12-11 | 結腸洗浄及び胃腸障害の治療のための組成物 |
| JP2025134346A Pending JP2025169325A (ja) | 2015-05-01 | 2025-08-12 | 結腸洗浄及び胃腸障害の治療のための組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020165328A Withdrawn JP2020203954A (ja) | 2015-05-01 | 2020-09-30 | 結腸洗浄及び胃腸障害の治療のための組成物 |
| JP2022107644A Pending JP2022121734A (ja) | 2015-05-01 | 2022-07-04 | 結腸洗浄及び胃腸障害の治療のための組成物 |
| JP2023208395A Active JP7862355B2 (ja) | 2015-05-01 | 2023-12-11 | 結腸洗浄及び胃腸障害の治療のための組成物 |
| JP2025134346A Pending JP2025169325A (ja) | 2015-05-01 | 2025-08-12 | 結腸洗浄及び胃腸障害の治療のための組成物 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10618938B2 (enExample) |
| EP (2) | EP4218789A3 (enExample) |
| JP (5) | JP6930919B2 (enExample) |
| KR (2) | KR20250042844A (enExample) |
| CN (2) | CN114716514A (enExample) |
| CA (2) | CA3172777A1 (enExample) |
| CY (1) | CY1126031T1 (enExample) |
| DK (1) | DK3288578T5 (enExample) |
| EA (1) | EA201792401A1 (enExample) |
| ES (1) | ES2947591T3 (enExample) |
| FI (1) | FI3288578T3 (enExample) |
| HR (1) | HRP20230381T1 (enExample) |
| HU (1) | HUE061954T2 (enExample) |
| LT (1) | LT3288578T (enExample) |
| MA (1) | MA41985B1 (enExample) |
| MD (1) | MD3288578T2 (enExample) |
| MX (2) | MX2017013928A (enExample) |
| PL (1) | PL3288578T3 (enExample) |
| PT (1) | PT3288578T (enExample) |
| RS (1) | RS64160B1 (enExample) |
| SI (1) | SI3288578T1 (enExample) |
| SM (1) | SMT202300114T1 (enExample) |
| WO (1) | WO2016178979A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10618938B2 (en) * | 2015-05-01 | 2020-04-14 | Ironwood Pharmaceuticals, Inc. | Compositions for colon cleansing and the treatment of gastrointestinal disorders |
| SI3464336T1 (sl) | 2016-06-01 | 2022-06-30 | Athira Pharma, Inc. | Spojine |
| CA3238634A1 (en) * | 2021-11-24 | 2023-06-01 | Christopher Leitheiser | Synthetic process for production of modified gcc receptor agonists |
| WO2023097210A1 (en) * | 2021-11-24 | 2023-06-01 | Ironwood Pharmaceuticals, Inc. | Synthetic process for production of modified gcc receptor agonists |
| EP4440595A1 (en) * | 2021-11-29 | 2024-10-09 | Ironwood Pharmaceuticals, Inc. | Pharmaceutical compositions for the treatment of visceral pain |
| WO2026050206A1 (en) * | 2024-08-27 | 2026-03-05 | Ironwood Pharmaceuticals, Inc. | Combinations of glp-1 and guanylate cyclase c (gc-c) receptor agonists |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH689139A5 (de) | 1995-04-03 | 1998-10-30 | Cerbios Pharma Sa | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung. |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| BR122018074353B8 (pt) * | 2003-01-28 | 2023-05-02 | Ironwood Pharmaceuticals Inc | composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos |
| US7494979B2 (en) * | 2003-06-13 | 2009-02-24 | Ironwood Pharmaceuticals, Inc. | Method for treating congestive heart failure and other disorders |
| EP1940441A4 (en) * | 2005-08-19 | 2010-01-27 | Ironwood Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL DISORDERS |
| US20110172126A1 (en) * | 2008-09-03 | 2011-07-14 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
| CA2790213A1 (en) * | 2010-02-17 | 2011-08-25 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| MX357121B (es) * | 2011-03-01 | 2018-06-27 | Synergy Pharmaceuticals Inc Star | Proceso de preparacion de agonistas c de guanilato ciclasa. |
| EP2958577A2 (en) * | 2013-02-25 | 2015-12-30 | Synergy Pharmaceuticals Inc. | Guanylate cyclase receptor agonists for use in colonic cleansing |
| PL3004138T3 (pl) * | 2013-06-05 | 2024-07-29 | Bausch Health Ireland Limited | Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie |
| WO2016015055A1 (en) | 2014-07-25 | 2016-01-28 | Ironwood Pharmaceuticals, Inc. | Colon cleansing compositions |
| US10618938B2 (en) | 2015-05-01 | 2020-04-14 | Ironwood Pharmaceuticals, Inc. | Compositions for colon cleansing and the treatment of gastrointestinal disorders |
-
2016
- 2016-04-29 US US15/570,838 patent/US10618938B2/en active Active
- 2016-04-29 RS RS20230311A patent/RS64160B1/sr unknown
- 2016-04-29 MD MDE20180232T patent/MD3288578T2/ro unknown
- 2016-04-29 JP JP2017557067A patent/JP6930919B2/ja active Active
- 2016-04-29 FI FIEP16721609.2T patent/FI3288578T3/fi active
- 2016-04-29 WO PCT/US2016/030061 patent/WO2016178979A1/en not_active Ceased
- 2016-04-29 KR KR1020257008457A patent/KR20250042844A/ko active Pending
- 2016-04-29 HR HRP20230381TT patent/HRP20230381T1/hr unknown
- 2016-04-29 SI SI201631712T patent/SI3288578T1/sl unknown
- 2016-04-29 CN CN202210288669.XA patent/CN114716514A/zh active Pending
- 2016-04-29 SM SM20230114T patent/SMT202300114T1/it unknown
- 2016-04-29 CN CN201680032088.2A patent/CN108040482B/zh active Active
- 2016-04-29 PT PT167216092T patent/PT3288578T/pt unknown
- 2016-04-29 CA CA3172777A patent/CA3172777A1/en active Pending
- 2016-04-29 MA MA41985A patent/MA41985B1/fr unknown
- 2016-04-29 PL PL16721609.2T patent/PL3288578T3/pl unknown
- 2016-04-29 CA CA2984437A patent/CA2984437C/en active Active
- 2016-04-29 EA EA201792401A patent/EA201792401A1/ru unknown
- 2016-04-29 EP EP23159398.9A patent/EP4218789A3/en active Pending
- 2016-04-29 MX MX2017013928A patent/MX2017013928A/es unknown
- 2016-04-29 LT LTEPPCT/US2016/030061T patent/LT3288578T/lt unknown
- 2016-04-29 ES ES16721609T patent/ES2947591T3/es active Active
- 2016-04-29 DK DK16721609.2T patent/DK3288578T5/da active
- 2016-04-29 HU HUE16721609A patent/HUE061954T2/hu unknown
- 2016-04-29 KR KR1020177034808A patent/KR102783759B1/ko active Active
- 2016-04-29 EP EP16721609.2A patent/EP3288578B8/en active Active
-
2017
- 2017-10-30 MX MX2022013283A patent/MX2022013283A/es unknown
-
2020
- 2020-09-30 JP JP2020165328A patent/JP2020203954A/ja not_active Withdrawn
-
2022
- 2022-07-04 JP JP2022107644A patent/JP2022121734A/ja active Pending
-
2023
- 2023-05-26 CY CY20231100253T patent/CY1126031T1/el unknown
- 2023-12-11 JP JP2023208395A patent/JP7862355B2/ja active Active
-
2024
- 2024-01-26 US US18/424,114 patent/US20240199697A1/en active Pending
-
2025
- 2025-08-12 JP JP2025134346A patent/JP2025169325A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1154655C (zh) | k受体的阿片样肽 | |
| ES2977537T3 (es) | Inhibidores peptídicos orales del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias intestinales | |
| CA2726917C (en) | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | |
| CA2726913C (en) | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | |
| KR20230110570A (ko) | 인터류킨-23 수용체의 펩티드 억제제의 조성물 | |
| TWI708790B (zh) | 芋螺毒素（ｃｏｎｏｔｏｘｉｎ）肽之修飾及用途 | |
| JP7862355B2 (ja) | 結腸洗浄及び胃腸障害の治療のための組成物 | |
| US8748575B2 (en) | Therapeutic peptides | |
| DK2536742T3 (en) | TREATMENTS FOR GASTROINTESTINAL DISORDERS | |
| RU2016101711A (ru) | Высокостабильный т-клеточный рецептор и способ его получения и применения | |
| RU2017146657A (ru) | Пролекарства, содержащие коньюгат гиалуроновой кислоты, ликера и и двойного агониста glp-1глюкагона | |
| JP2010507565A (ja) | メタスチン誘導体およびその用途 | |
| NZ554021A (en) | Specific binding agents of human angiopoietin-2 | |
| JP2016515620A5 (enExample) | ||
| JP2016515620A (ja) | 新規のα４β７ペプチド拮抗薬 | |
| CN105579467A (zh) | 用于治疗炎性疾病和/或免疫疾病的皮质抑素类似物 | |
| KR20120105429A (ko) | 염증 치료 방법 | |
| US20170173107A1 (en) | Compstatin Analogs With Improved Potency and Pharmacokinetic Properties | |
| US9650417B2 (en) | Treatments for gastrointestinal disorders | |
| JP2020037570A (ja) | オピオイド誘発性機能障害の治療に有用なグアニル酸シクラーゼのアゴニスト | |
| JP2022525416A (ja) | ペプチド模倣大環状分子およびその使用 | |
| CN102574904A (zh) | 赋予了经粘膜吸收性的胃动素样肽化合物 | |
| US20140342996A1 (en) | Treatments for Gastrointestinal Disorders | |
| US20230321188A1 (en) | Autophagy inducing peptides | |
| CN108884130B (zh) | 用于治疗溃疡性结肠炎的制剂和方法 |